CAS 88899-55-2|Bafilomycin A1
Introduction：Basic information about CAS 88899-55-2|Bafilomycin A1, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Bafilomycin A1 | ||
|---|---|---|---|
| CAS Number | 88899-55-2 | Molecular Weight | 622.830 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 770.1±60.0 °C at 760 mmHg |
| Molecular Formula | C35H58O9 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 232.2±26.4 °C |
Names
| Name | bafilomycin A1 |
|---|---|
| Synonym | More Synonyms |
Bafilomycin A1 BiologicalActivity
| Description | Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of vacuolar-type H+ ATPase. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Proton PumpResearch Areas >>CancerResearch Areas >>Infection |
| Target | H+ ATPase[1] |
| In Vitro | Bafilomycin A1 at a low concentration (1 nM) effectively and specifically inhibits and kills pediatric B-cell acute lymphoblastic leukemia cells. It targets both early and late stages of the autophagy pathway, mitochondria and induces caspase-independent apoptosis. Bafilomycin A1 induces the binding of Beclin 1 to Bcl-2, which further inhibits autophagy and promotes apoptotic cell death[1]. The growth of the BEL-7402 hepatocellular carcinoma and HO-8910 ovarian cancer cell lines are retarded and the metastatic potential is inhibited by bafilomycin A1. Transmission electron microscopy and assays of capsase-3 and −9 suggest that bafilomycin A1 induces apoptosis[2]. Bafilomycin A1 inhibits the growth of a variety of cultured cells dose-dependently, including golden hamster embryo and NIH-3T3 fibroblasts, whether or not they are transformed, and PC12 and HeLa cells. The IC50 of bafilomycin A1 for inhibition of cell growth ranges from 10 to 50 nM[3]. |
| In Vivo | Chronic treatment with low-dose bafilomycin A1 (0.1 mg/kg) slightly inhibits the tumor volume, but the final tumor volume does not differ significantly from the control. However, chronic treatment with high dose bafilomycin A1 (1 mg/kg) inhibits the tumor growth significantly, compared with controls, after 21 days[4]. |
| Cell Assay | Cells are harvested using 0.05% trypsin and suspended in culture medium containing 10% FCS, and 200 µL suspension is added to each well of a 96-well plate. Cells are cultured for 20 h for adhesion. Bafilomycin A1 is added to the wells at the final concentrations of 200, 400 and 800 nM, in triplicate. At 24, 48 and 72 h, 20 µl WST-1 is added to the cells. Following incubation at 37°C for 4 h, the plates are read to determine the optical density (OD) at 435 nm with 675 nm reference using a spectrophotometer[2]. |
| Animal Admin | Mice: Tumor-bearing mice are divided randomly into three experimental groups: a low-dose bafilomycin A1(0.1 mg/kg per day)-treated group (n=5), a high-dosebafilomycin A1(1 mg/kg per day)-treated group (n=5),and a control group (n=5). Tumor size is measured and tumor volume doubling time is calculated[2]. |
| References | [1]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56. [2]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834. [3]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6. [4]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30. |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 770.1±60.0 °C at 760 mmHg |
| Molecular Formula | C35H58O9 |
| Molecular Weight | 622.830 |
| Flash Point | 232.2±26.4 °C |
| Exact Mass | 622.408081 |
| PSA | 134.91000 |
| LogP | 3.88 |
| Vapour Pressure | 0.0±6.0 mmHg at 25°C |
| Index of Refraction | 1.535 |
| InChIKey | XDHNQDDQEHDUTM-PXKWMJKESA-N |
| SMILES | COC1=CC(C)=CC(C)C(O)C(C)CC(C)=CC=CC(OC)C(C(C)C(O)C(C)C2(O)CC(O)C(C)C(C(C)C)O2)OC1=O |
| Storage condition | -20°C |
Safety Information
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
|---|---|
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | UN 3172 |
| WGK Germany | 3 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
Articles41
More Articles| SUMO1 promotes Aβ production via the modulation of autophagy. Autophagy 11(1) , 100-12, (2015) Autophagy is one of the main mechanisms in the pathophysiology of neurodegenerative disease. The accumulation of autophagic vacuoles (AVs) in affected neurons is responsible for amyloid-β (Aβ) product... | |
| GA binding protein augments autophagy via transcriptional activation of BECN1-PIK3C3 complex genes. Autophagy 10(9) , 1622-36, (2014) Macroautophagy is a vesicular catabolic trafficking pathway that is thought to protect cells from diverse stressors and to promote longevity. Recent studies have revealed that transcription factors pl... | |
| Autophagy facilitates secretion and protects against degeneration of the Harderian gland. Autophagy 11(2) , 298-313, (2015) The epithelial derived Harderian gland consists of 2 types of secretory cells. The more numerous type A cells are responsible for the secretion of lipid droplets, while type B cells produce dark granu... |
Synonyms
| (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-5-isopropyl-4-methyl-α-D-threo-pentopyranose |
| α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)- |
| 21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-hygrolidin |
| bafilomycin A |
| MFCD06795130 |
| Oxacyclohexadeca-3,5,11,13-tetraen-2-one, 8-hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11- |
| α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-met hylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)- |
| (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4- ;methyl-α-D-threo-pentopyranose |
| BafilomycinA1fromStreptomycesgriseus |
| (5R)-2,4-Dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(3S,4Z,6Z,9S,10S,11R,12Z,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2-pentanyl}-5-isopropyl-4-met ;hyl-α-D-threo-pentopyranose |
| BAFILOMYCIN A1 |
| bafilomycin |
| tetramethyl-, (3Z,5E,7R,8S,9S,11E,13E,15S,16R)- |
| (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-Methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-Methyl-6-(1-Methylethyl)-2H-pyran-2-yl]butyl]-3,15-diMethoxy-5,7,9,11-tetraMethyloxacyclohexadeca-3,5,11,13-tetraen-2-o |
| (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-((1S,2R,3S)-2-hydroxy-1-methyl-3-((2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5 |
| Bafilomycin A1 from Streptomycesgriseus,10 ug |
| α-D-threo-Pentopyranose, 2,4-dideoxy-1-C-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14Z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1- methylbutyl]-4-methyl-5-C-(1-methylethyl)-, (5R)- |
